RESOMER RG 858 S Bioresorbable PLGA Drug Delivery Grade is an ester-terminated poly(D,L-lactide-co-glycolide) copolymer with a nominal D,L-lactide-to-glycolide molar ratio of 85:15. The material is assigned CAS RN 26780-50-7 and is supplied as a high-inherent-viscosity solid for parenteral and implantable drug delivery platforms. Because the D,L-lactide stereocomposition is racemic, the copolymer is amorphous rather than semicrystalline, and it lacks the discrete melting endotherm characteristic of poly(L-lactide) homopolymers. The resin is manufactured under controlled conditions with residual monomer, residual tin, and water content specified on the certificate of analysis. The ester-capped chain terminus distinguishes RG 858 S from acid-terminated PLGA grades of similar comonomer ratio and strongly influences the early-stage degradation pH environment and polymer–drug interaction profile.

The product targets diffusion-controlled release applications where extended residence time is required. It is used in organic-solvent-based microsphere preparation, solvent casting, and melt extrusion of bioresorbable implants. In the microsphere route, the polymer is commonly dissolved in dichloromethane at solids loadings between 10% w/w and 20% w/w, then emulsified with aqueous polyvinyl alcohol. The high solution viscosity associated with this grade requires high-shear dispersion but also stabilizes the primary emulsion against early coalescence. In melt-processing lines, the amorphous architecture permits extrusion below the thermal decomposition threshold, provided barrel residence time and shear heating are controlled.

What Limits Solvent Residuals in High-Lactide PLGA Microsphere Drying?

Solvent removal in microsphere manufacturing is constrained by the high glass transition temperature, the amorphous structure, and the tendency of dichloromethane to plasticize the PLGA matrix. Dichloromethane has a boiling point of 39.6 °C and water solubility of approximately 1.3% w/w; these properties enable extraction into aqueous continuous phases, but residual solvent pockets can remain in the core of particles above 20 µm if solvent replacement is too rapid. Production-scale extraction baths are typically operated with a temperature ramp from 15 °C to 25 °C, followed by vacuum drying at 25–35 °C for 12–24 h. The dichloromethane residual is controlled against the ICH Q3C Class 2 limit of 600 ppm. For sensitive peptide or protein payloads, ethyl acetate or benzyl alcohol has been evaluated in published microencapsulation studies; however, dichloromethane remains the most predictable solvent for high-molecular-weight 85:15 PLGA because its extraction kinetics are better documented across pilot-scale mixer geometries.

The values above are grade-family control ranges and do not replace lot-specific release data. Confirm each shipment against the manufacturer certificate of analysis because residual tin and monomer levels can vary slightly with batch size and finishing conditions.

Hydrolytic degradation of 85:15 PLGA proceeds by random chain scission of ester bonds in the polymer backbone. The higher lactide content reduces water uptake relative to 50:50 PLGA, while the ester terminal group reduces the initial concentration of free carboxylic acid in the dry polymer. In a low-buffer-capacity environment, degradation products can accumulate and produce an acidic microclimate; this autocatalytic effect is less pronounced in 85:15 PLGA than in 50:50 PLGA because the more hydrophobic matrix retards water ingress. In vitro degradation testing under ASTM F1635-16 at pH 7.4 and 37 °C generally places mass loss for high-molecular-weight 85:15 PLGA beyond 3 months, whereas 50:50 benchmarks often lose measurable mass within 1–2 months. Published data for erosion rates are highly dependent on specimen geometry, film thickness, and molecular weight; no single degradation half-life applies across all finished-device configurations.

When Ester Termination Replaces Acid Capping in 85:15 PLGA Grades

Ester-terminated PLGA grades such as RG 858 S display a lower initial carboxylic acid content than acid-terminated analogues. This difference is relevant in peptide and ionizable small-molecule formulations where the terminal acid can protonate basic APIs, promote acyl migration, or accelerate degradation during solvent evaporation. The ester terminus does not eliminate acid generation during storage or use; hydrolysis of backbone ester bonds generates new carboxylic acid and alcohol end groups, and the degradation process remains autocatalytic. However, the effect of ester termination is most pronounced in the early lag phase before bulk water uptake and chain scission become extensive. In stability studies, formulations containing acid-terminated PLGA have shown faster initial moisture sorption and higher headspace acidity than ester-terminated equivalents of the same lactide-to-glycolide ratio, although the magnitude is formulation-dependent and should be measured directly by pH-stability testing of the drug-polymer matrix.

On production-scale twin-screw extruders with L/D ratios of 25:1 to 40:1, high-viscosity PLGA grades are typically processed at barrel temperatures from 160 °C to 190 °C and screw speeds below 100 rpm to limit shear heating. RG 858 S produces higher torque and higher die pressure than lower-inherent-viscosity grades at identical throughput, and the melt viscosity can vary noticeably with residual moisture. Pre-drying at 25–35 °C under vacuum to moisture ≤ 0.1% is recommended if ambient relative humidity exceeds 60% for more than 4 h. The polymer should not be combined with amine-based additives or strong bases because these species accelerate ester hydrolysis and can reduce molecular weight during extrusion. If terminal sterilization is required, gamma irradiation can reduce molecular weight and modify release; dose mapping on the finished device is necessary because the effect is lot- and formulation-dependent.

Thermal Degradation Windows in Twin-Screw and Molded Implant Processing

Thermal degradation of PLGA involves intramolecular transesterification and β-elimination reactions that generate lactide and glycolide monomers and low-molecular-weight fragments. Thermogravimetric analysis of high-lactide PLGA typically shows onset of mass loss near 250 °C under nitrogen, but chain scission can begin at lower temperatures when residence time is extended. Melt-processing operations should remain below 200 °C and keep residence times under 5–10 min to preserve inherent viscosity. Because RG 858 S is amorphous, no crystalline melting zone must be cleared before extrusion; the material softens above its glass transition temperature and can be shaped at temperatures lower than those used for semicrystalline PLLA. Molded implant trials on electrically heated laboratory presses with platen temperatures of 110–130 °C have been used to prepare monolithic drug-loaded disks, although compression force, hold time, and API thermal stability require separate optimization.

Release Kinetic Differences Across 85:15, 75:25, and 50:50 PLGA Benchmarks

Higher lactide content reduces water uptake, slows ester hydrolysis, and shifts the release mechanism from erosion-dominated to diffusion-dominated transport. 50:50 PLGA grades are more hydrophilic and typically release loaded small molecules over weeks to approximately 2 months. 75:25 PLGA occupies an intermediate position, with a slower moisture ingress profile and longer erosion interval. 85:15 PLGA such as RG 858 S extends release further, often into the 3–5 month range in microsphere formats, although the actual duration depends on particle size, drug loading, porosity, and molecular weight. The high inherent viscosity of this grade reduces burst release by increasing matrix tortuosity and retarding drug diffusion, but it also raises solution viscosity during solvent-based microsphere manufacturing. Low-inherent-viscosity grades are generally preferred for nanoprecipitation or nanoemulsion routes, while RG 858 S is better suited to microsphere, implant, and long-acting depot formats where a robust matrix is required.

Operational boundaries include sensitivity to moisture during storage and handling, limited solubility in water, and incompatibility with alkaline processing media. Aqueous dispersions of the neat polymer cannot be prepared without organic solvent or elevated pH, and the high molecular weight prevents bulk sterile filtration through 0.22 µm membranes. These constraints restrict the product to processing routes that tolerate organic solvents or melt processing and require aseptic design or terminal sterilization of the finished product. Published comparative data for RG 858 S under all production-scale conditions are limited; processing parameters should therefore be confirmed with benchtop and pilot studies on the specific drug substance and final device geometry.